BioArctic is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs.

Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

Objective and strategy

Our ambition is to build an innovative and competitive portfolio of drug candidates, diagnostics and technology for the indications in which we operate.

Collaborations and partners

We strive to be an attractive and leading partner in our research areas for research groups at universities, pharma companies and in health care.

Culture and values

In order to accomplish our vision and mission BioArctic encourages a strong culture of curiosity and innovation among our employees and partners.